Company performance
Current Price
as of Jan 17, 2025$0.95
P/E Ratio
N/A
Market Cap
$63.32M
- PVT
Description
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerGBIO
- Price$0.948+0.18%
Trading Information
- Market cap$63.32M
- Float63.43%
- Average Daily Volume (1m)645,632
- Average Daily Volume (3m)381,272
- EPS-$2.19
Company
- Revenue$18.58M
- Rev growth (1yr)252.00%
- Net income-$15.31M
- Gross margin84.38%
- EBITDA margin-205.65%
- EBITDA-$15.54M
- EV$73.85M
- EV/Revenue3.97
- P/EN/A
- P/S3.40
- P/B0.61
Documents
SEC Filings
Factset Street Account